While expression of HOXB13 remains high throughout prostate tumors and metastases, we previously demonstrated a step-wise decrease in MEIS1 and MEIS2 expression from benign epithelium to tumor and metastasis and that MEIS-positive prostate tumors confer an overall favorable patient outcome, thus implying that MEIS-HOXB13 interactions are tumor-suppressive (Bhanvadia et al., 2018). This evidence concerns the gene MEIS2 and prostate neoplasm.